Psychiatry Research
June 1, 2025
Jeremy Weleff, Alejandra Pulido-Saavedra, Ardavan Mohammad Aghaei et al.
4 citations
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...
Cellular and molecular life sciences : CMLS
January 21, 2025
Alejandra Pulido-Saavedra, Henrique Nunes Pereira Oliva, Tiago Paiva Prudente et al.
5 citations
The current opioid crisis has had an unprecedented public health impact. Approved medications for opioid use disorder (OUD) exist, yet their limitations indicate a need for innovative treatments. Limited preliminary clinical studies suggest specific psychedelics might aid OUD treatment, though most clinical evidence remains observational, with few controlled trials. This review aims to bridge...
Frontiers in Psychiatry
2025
Scott Matthews, Antonino Greco, Clara Rastelli et al.
1 citation
Psychedelic-assisted therapy is a remarkably promising treatment for substance use disorders and for alcohol use disorder (AUD) in particular. Research supporting psychedelics as a safe and effective pharmacotherapy for AUD and its comorbid psychiatric conditions dates from the late1940s and includes over 2,000 published studies. There are, however, challenges to the clinical implementation of...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Psychopharmacology
October 1, 2024
Ardavan Mohammad Aghaei, Lia Urban Spillane, Brian Pittman et al.
9 citations
Recent reports have shown increased cannabis use among women, leading to growing concerns about cannabis use disorder (CUD). While there is preclinical evidence suggesting biological sex influences cannabinoid effects, human research remains scant. We investigated sex differences in the acute response to oral tetrahydrocannabinol (THC) in humans. 56 healthy men and women with prior exposure to...
Frontiers in Psychiatry
October 19, 2023
Brian S. Barnett, Anahita Bassir Nia, Nathan Sackett et al.
1 citation
Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...